Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells

Cornea

Volumn 27, Issue 8, 2008, Pages 930-934

  Sosa, Alejandro Babayán ^a   Epstein, Seth P ^a   Asbell, Penny A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic toxicity; Fluoroquinolone antibiotics; Gatifloxacin; Levofloxacin; Moxifloxacin; Toxicity assay

Indexed keywords

2 PROPANOL; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CIPROFLOXACIN; FORMALDEHYDE; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SODIUM CHLORIDE; ANTIINFECTIVE AGENT; EYE DROPS; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ABSORPTION; ARTICLE; CELL ASSAY; CELL DEATH; CELL IMMORTALIZATION; CONCENTRATION RESPONSE; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CORNEA CELL; CORNEA EPITHELIUM; CULTURE MEDIUM; DRUG CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; TISSUE CULTURE; TOXICITY TESTING; WOUND HEALING; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CONJUNCTIVA; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; METABOLISM; PATHOLOGY;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CELL LINE; CELL SURVIVAL; CIPROFLOXACIN; CONJUNCTIVA; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; EPITHELIUM, CORNEAL; FLUOROQUINOLONES; HUMANS; OFLOXACIN; OPHTHALMIC SOLUTIONS; QUINOLINES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 50549094168     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31816f27ab     Document Type: Article

References (36)

1. Blondeau JM. Fluoroquinolones: mechanism of action, classification and development of resistance. Surv Ophthalmol. 2004;49(Suppl 2):S73-S78.
2. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49(Suppl 2):S79-S83.
3. Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolones resistance in bacterial keratitis. A 5-year review. Ophthalmology. 1999; 106:1313-1318.
4. Chaudhry NA, Flynn HW, Murray TG, et al. Emerging ciprofloxacinresistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128: 509-510.
5. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
6. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15:316-320.
7. Mallari PL, McCarty DJ, Daniell M, et al. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001;131:131-133.
8. Reviglio VE, Hakim MA, Song JK, et al. Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol. 2003;3:10.
9. Yalvac IS, Gedikoglu G, Karagoz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
10. Arici MK, Arici DS, Topalkara A, et al. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol. 2000;28: 113-117.
11. Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2001;239:809-814.
12. Takahashi N. Quantitative cytotoxicity of preservatives evaluated in cell culture with Chang's human conjunctival cell-effect of temperature on cytotoxicity. Jpn J Ophthalmol. 1982;26:234-238.
13. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang's conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42:642-652.
14. Geerling G, Daniels JT, Dart JK, et al. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:948-956.
15. Cha SH, Lee JS, Oum BS, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004; 32:180-184.
16. Takahashi N. Cytotoxicity of mercurial preservatives in cell culture. Ophthalmic Res. 1982;14:63-69.
17. Offord EA, Sharif NA, Macé K, et al. Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Invest Ophthalmol Vis Sci. 1999;40:1091-1101.
18. Ubels JL, Clousing DP, Van Haitsma T, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eye Res. 2004;28:437-444.
19. Nakamura S, Okada S, Umeda Y, et al. Development of a rabbit model of tear film instability and evaluation of viscosity of artificial tear preparations. Cornea. 2004;23:390-397.
20. Puhlev I, Guo N, Brown DR, et al. Desiccation tolerance in human cells. Cryobiology. 2001;42:207-217.
21. Dixon WJZ, Massey FJ. Introduction to Statistical Analysis. 3rd ed. New York: McGraw-Hill; 1969.
22. Hoel PH, Port SC, Stone CJ. Introduction to Statistical Theory, vol. 2. Boston: Houghton Mifflin; 1971.
23. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005;112:466-469.
24. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Opththalmol. 2003;136:500-505.
25. Asbell PA, Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocul Surf. 2005;3:27-40.
26. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215.
27. Noecker R, Herrygers L, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23:490-496.
28. Patel GM, Chuang AZ, Kiang E, et al. Epithelial healing rates with topical ciprofloxacin, ofloxacin, and ofloxacin with artificial tears after photorefractive keratectomy. J Cataract Refract Surg. 2000;26:690-694.
29. Yee RW, Sorour SB, Yee AZ, et al. Comparison of relative toxicity of four antibiotics using the human corneal epithelial cell culture system. Invest Ophthalmol Vis Sci. 2004;45(Suppl):4939.
30. Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens. 2004;30:90-94.
31. Ly LT, Cavanagh HD, Petroll WM. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Eye Contact Lens. 2006;32:161-5.
32. Baez E, Hyon JY, Zhang C, et al. In vivo toxicity of preserved and self-preserved antibiotics in mouse corneal keratocytes. Invest Ophthalmol Vis Sci. 2005;46(Suppl):4909.
33. Herrygers LA, Noecker RJ, Lane LC, et al. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Cornea. 2005;24:66-71.
34. Donnenfeld E, Perry HD, Chruscicki DA, et al. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin. 2004;20:1753-1758.
35. Nguyen QH, Friedlaender MH, Sharf L, et al. Objective and subjective measurement of drug toxicity. Invest Ophthalmol Vis Sci. 2004;45(Suppl): 4937.
36. Wagner RS, DÆArienzo PA, Hallas SJ, et al. A comparative study in a normal pediatric population of the relative comfort of moxifloxacin 0.5% ophthalmic solution versus a tear substitute. Invest Ophthalmol Vis Sci. 2004;45(Suppl):4936.